G
Gabrielle T. Prince
Researcher at Johns Hopkins University
Publications - 44
Citations - 2187
Gabrielle T. Prince is an academic researcher from Johns Hopkins University. The author has contributed to research in topics: Medicine & Myeloid leukemia. The author has an hindex of 15, co-authored 35 publications receiving 1521 citations. Previous affiliations of Gabrielle T. Prince include Johns Hopkins University School of Medicine.
Papers
More filters
Journal ArticleDOI
Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML
Courtney D. DiNardo,Eytan M. Stein,S. de Botton,Gail J. Roboz,Jessica K. Altman,Alice S. Mims,Ronan T. Swords,Robert H. Collins,Gabriel N. Mannis,Daniel A. Pollyea,William B. Donnellan,Amir T. Fathi,A. Pigneux,Harry P. Erba,Gabrielle T. Prince,Anthony S. Stein,Geoffrey L. Uy,James M. Foran,Elie Traer,Robert K. Stuart,Martha Arellano,James L. Slack,Mikkael A. Sekeres,Christophe Willekens,Sung Choe,Hongfang Wang,Vickie Zhang,Katharine E. Yen,Stephanie M. Kapsalis,Hua Yang,David Dai,Bin Fan,Meredith Goldwasser,Hua Liu,Samuel V. Agresta,Bin Wu,Eyal C. Attar,Martin S. Tallman,Richard Stone,Hagop M. Kantarjian +39 more
TL;DR: In patients with advanced IDH1‐mutated relapsed or refractory AML, ivosidenib at a dose of 500 mg daily was associated with a low frequency of grade 3 or higher treatment‐related adverse events and with transfusion independence, durable remissions, and molecular remissions in some patients with complete remission.
Journal ArticleDOI
Risk-stratified outcomes of nonmyeloablative, HLA-haploidentical BMT with high-dose posttransplantation cyclophosphamide
Shannon R. McCurdy,Jennifer A. Kanakry,Margaret M. Showel,Hua Ling Tsai,Javier Bolaños-Meade,Gary L. Rosner,Christopher G. Kanakry,Karlo Perica,Heather J. Symons,Robert A. Brodsky,Douglas E. Gladstone,Carol Ann Huff,Keith W. Pratz,Gabrielle T. Prince,Amy E. DeZern,Ivana Gojo,William Matsui,Ivan Borrello,Michael A. McDevitt,Lode J. Swinnen,B. Douglas Smith,Mark J. Levis,Richard F. Ambinder,Leo Luznik,Richard J. Jones,Ephraim J. Fuchs,Yvette L. Kasamon +26 more
TL;DR: This analysis demonstrates that the DRI effectively risk stratifies recipients of NMA HLA-haploidentical BMT with PTCy and suggests that this transplantation platform yields similar survivals to those seen with HLA -matched BMT.
Journal ArticleDOI
Ivosidenib induces deep durable remissions in patients with newly diagnosed IDH1-mutant acute myeloid leukemia
Gail J. Roboz,Courtney D. DiNardo,Eytan M. Stein,Stéphane de Botton,Alice S. Mims,Gabrielle T. Prince,Jessica K. Altman,Martha Arellano,Will Donnellan,Harry P. Erba,Gabriel N. Mannis,Daniel A. Pollyea,Anthony S. Stein,Geoffrey L. Uy,Justin M. Watts,Amir T. Fathi,Hagop M. Kantarjian,Martin S. Tallman,Sung Choe,David Dai,Bin Fan,Hongfang Wang,Vickie Zhang,Katharine E. Yen,Stephanie M. Kapsalis,Denice Hickman,Hua Liu,Samuel V. Agresta,Bin Wu,Eyal C. Attar,Richard Stone +30 more
TL;DR: Ivosidenib monotherapy was well tolerated and induced durable remissions and transfusion independence in patients with newly diagnosed acute myeloid leukemia (AML).
Journal ArticleDOI
Outcomes of Nonmyeloablative HLA-Haploidentical Blood or Marrow Transplantation With High-Dose Post-Transplantation Cyclophosphamide in Older Adults
Yvette L. Kasamon,Javier Bolaños-Meade,Gabrielle T. Prince,Hua Ling Tsai,Shannon R. McCurdy,Jennifer A. Kanakry,Gary L. Rosner,Robert A. Brodsky,Karlo Perica,B. Douglas Smith,Douglas E. Gladstone,Lode J. Swinnen,Margaret M. Showel,William Matsui,Carol Ann Huff,Ivan Borrello,Keith W. Pratz,Michael A. McDevitt,Ivana Gojo,Amy E. DeZern,Satish Shanbhag,Mark J. Levis,Leo Luznik,Richard F. Ambinder,Ephraim J. Fuchs,Richard J. Jones +25 more
TL;DR: NMA haplo-BMT with post-transplantation cyclophosphamide has encouraging safety and survival outcomes in patients age 50 to 75 years, and in patients otherwise fit for BMT, the results support consideration of this approach despite advanced age.
Journal ArticleDOI
Multi-Center Phase 2 Study of Pembroluzimab (Pembro) and Azacitidine (AZA) in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML) and in Newly Diagnosed (≥65 Years) AML Patients
Ivana Gojo,Robert K. Stuart,Jonathan Webster,Amanda L. Blackford,Juan C. Varela,Jillian Morrow,Amy E. DeZern,Matthew C. Foster,Mark J. Levis,Catherine C. Coombs,Gabrielle T. Prince,B. Douglas Smith,Hendrik W. van Deventer,Katarzyna Jamieson,Ravi Varadhan,Benjamin G. Vincent,Jonathan S. Serody,Leo Luznik,Joshua F. Zeidner +18 more
TL;DR: To assess safety and response to AZA/Pembro after minimum 2 cycles of therapy in relapsed/refractory AML and newly diagnosed (dx) older AML, patients with prior allogeneic stem cell transplant (alloSCT) were included and Cohort 2 started enrollment.